Pre-made Azintuxizumab benchmark antibody ( Whole mAb ADC, anti-SLAMF7/CS1 therapeutic antibody, Anti-19A/CD319/CRACC Antibody) for drug discovery and mechanism of action (MOA) research

Pre-Made Azintuxizumab biosimilar, Whole mAb ADC, Anti-SLAMF7/CS1 Antibody: Anti-19A/CD319/CRACC therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-ab-043-1mg	1mg	Inquiry
GMP-Bios-ab-043-10mg	10mg	Inquiry
GMP-Bios-ab-043-100mg	100mg	Inquiry
GMP-Bios-ab-043-xmg	≥100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Azintuxizumab biosimilar, Whole mAb ADC, Anti-SLAMF7/CS1 Antibody: Anti-19A/CD319/CRACC therapeutic antibody
INN Name	Azintuxizumab
Target	CS1
Format	Whole mAb ADC
Derivation	Humanized
Species Reactivity	Human
CH1 Isotype	IgG1
VD LC	Kappa
Highest_Clin_Trial (Jan '20)	Phase-I
Est. Status	Discontinued
100% SI Structure	None
99% SI Structure	None
95-98% SI Structure	None
Year Proposed	2016
Year Recommended	2017
Companies	AbbVie
Conditions Approved	na
Conditions Active	na
Conditions Discontinued	Multiple myeloma
Development Tech	na